Search | Clinical Trials Finder

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more

Conditions: Major Depressive Disorder, MDD, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 93
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Bipolar Disorder, Major Depression
Interventions: Selective Serotonin Reuptake Inhibitor (SSRI); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 15 Years to 30 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Generalized Anxiety Disorder, Panic Disorder
Interventions: Niravam, SSRI/SNRI; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Treatment Resistant Depression
Interventions: ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR; Drug
Lead sponsor: Alar Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more

Conditions: Depression, Selective Serotonin Reuptake Inhibitor
Interventions: Not listed
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions: AXS-05 (dextromethorphan and bupropion) oral tablets; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 51
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more

Conditions: Sexual Dysfunctions, Psychological, Depression
Interventions: flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 42
States / cities: Costa Mesa, California • Fresno, California • National City, California + 36 more

Conditions: Anxious Depression, Depression
Interventions: Escitalopram, Duloxetine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder
Interventions: Cognitive-behavioral therapy, Psychotropic medication optimization, Treatment as Usual; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,004 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 1 more

Conditions: Anxiety
Interventions: Acamprosate; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Major Depressive Disorder
Interventions: Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate, High Dose Creatine Monohydrate, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Depression
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression, Major Depressive Disorder
Interventions: Clinical decision support tool; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 64 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Major Depressive Disorder
Interventions: ABX-002, Placebo; Drug · Other
Lead sponsor: Autobahn Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 44 more

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 79
States / cities: Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more

Conditions: Depression, Major Depressive Disorder
Interventions: AXS-05, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 43
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 39 more

Conditions: Depressive Disorder, Major
Interventions: Standard of Care (SOC); Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: 5-hydroxytryptophan and Creatine, Placebo control; Drug · Other
Lead sponsor: Brent Michael Kious, MD, PhD; Other
Eligibility: 25 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Major Depressive Disorder
Interventions: Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 35
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Major Depressive Disorder
Interventions: EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo; Drug
Lead sponsor: Euthymics BioScience, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 43
States / cities: Arcadia, California • Beverly Hills, California • National City, California + 39 more

Conditions: Major Depressive Disorder (MDD)
Interventions: GeneSight Psychotropic; Genetic
Lead sponsor: Assurex Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 61
States / cities: Birmingham, Alabama • Bellflower, California • Chino, California + 52 more

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

Multiple Ascending Dose Phase 1 Study of ALA-3000

Impact of Depression on Thermoregulation

Open-Label Safety Study of AXS-05 in Subjects With Depression

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

Primary Care Intervention Strategy for Anxiety Disorders

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

5-HTP and Creatine for Depression R33 Phase

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

Augmented Human Intelligence in Major Depressive Disorder

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

A Trial of AXS-05 in Patients With Major Depressive Disorder

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females

VA Augmentation and Switching Treatments for Improving Depression Outcomes

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Genomics Used to Improve DEpression Decisions